Sequence: KKALLAHALHLLALLALHLAHALKKA-NH2
| Experiment Id | EXP001251 |
|---|---|
| Paper | Reversal of ovarian cancer multidrug resistance by a combination of LAH4-L1-siMDR1 nanocomplexes wit |
| Peptide | LAH4-L1 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 2 µg siMDR1 per well (6-well plate) |
| Mixing Ratio | w/w LAH4-L1:siRNA = 3:1 (optimized) |
| Formulation Format | Self-assembled peptide/siRNA nanocomplex (electrostatic) |
| Formulation Components | LAH4-L1 + siRNA in 0.9% NaCl; incubate 20 min RT |
| Size Nm | 133.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | SKOV-3 (human multidrug-resistant ovarian cancer) |
| Animal Model | |
| Administration Route | |
| Output Type | MDR1 mRNA knockdown (%) |
| Output Value | 87.3 |
| Output Units | |
| Output Notes | Also ~85% P-gp down-regulation; enhanced chemosensitivity (PTX/DOX) after knockdown; uptake by flow cytometry/CLSM; endosomal escape by LysoTracker colocalization and bafilomycin A1 inhibition. |
| Toxicity Notes | Low cytotoxicity reported by CCK8 at 48 h post-transfection (optimized ratio). |
| Curation Notes |